Addiction

Papers
(The H4-Index of Addiction is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling267
An Addiction series on regional perspectives on addiction‐related problems244
Society for the Study of Addiction Annual Conference 2024111
108
102
Does recreational cannabis legalization change cannabis use patterns? Evidence from secondary school students in Uruguay100
Commentary on Lange et al.: Acute alcohol use before suicide—is it contributing to an increase in suicide rates in the United States?99
The use of financial incentives for smoking cessation in pregnant women: A parallel‐group randomised controlled trial protocol83
Recent decline in Chinese alcohol production and consumption: Potential contributing factors and the role of globally recommended measures78
Use of cessation products, e‐cigarettes and cigarette cessation outcomes among adults with substance use problems: Results from 2013–2021 (Waves 1–6) of the Population Assessment of Tobacco and Health77
Structure and stability of internet gaming disorder from childhood to late adolescence: A 5‐wave birth cohort study73
Risk of readmission among individuals with cannabis use disorder during a 15‐year cohort study: the impact of socio‐economic factors and psychiatric comorbidity66
Will Australia's tightened prescription system reduce nicotine vaping among young people?63
Estimating recent trends in alcohol sales in the United Kingdom from alcohol duty revenue63
Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms62
Assessing the impacts of alcohol outlets on crime as a natural experiment: agglomeration, churning and spatial effects60
Naloxone administration—no balance without titration58
Response to Hall et al.: Prescription psychostimulants for amphetamine‐type stimulant use disorder ‐ acknowledging challenges but not giving up on its potential cost‐effectiveness58
Quantifying alcohol‐attributable disability‐adjusted life years to others than the drinker in Aotearoa/New Zealand: A modelling study based on administrative data55
Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis54
Age, period and cohort effects of heavy episodic drinking by sex/gender and socioeconomic position in Canada, 2000–202149
Nicotine strength of e‐liquids used by adult vapers in Great Britain: A population survey 2016 to 202449
Chronic obstructive pulmonary disease in heroin users: An underappreciated issue with clinical ramifications49
Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data45
Evaluating the optimal duration of medication treatment for opioid use disorder44
Commentary on Stull et al.: Considering person‐specific heterogeneity when modeling time‐varying trends40
Significant changes in preference of illicit drug use in a population of Hanoi, Vietnam—A 6‐year wastewater study (2018–2023)38
ABC‐training as a new intervention for hazardous alcohol drinking: Two proof‐of‐principle randomized pilot studies37
Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial36
Impulsivity behaviors and white matter mediate the relationship between genetic risk for cannabis use disorder and early cannabis use in adolescents36
35
National profile on substance use, substance use‐related problems and policy: The case of Chile35
Rare but relevant series35
Austin Bradford Hill’s ‘Environment and disease: Association or causation’35
The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis35
0.22100496292114